ROIV Stock Card: Scores, Risk & Setup | Stoxcraft

Roivant Sciences Ltd.

Health

Performance

3.6

Risk

Sell

Buy

Curious about the Scores? Learn more.

Roivant Sciences Ltd. stock rating and score history

All changes in ratings, performance and outlook tracked over time.

01.07.2026

Danger zone. Balance sheet’s flashing red across the board.

18.06.2026

From average to promising. Starting to shine again.

12.06.2026

Calmer waters ahead. Risk signals cooling off.

12.10.2025

Outperforming hard. Momentum locked in.

ROIV

Roivant Sciences Ltd.

34.42

-0.26%

3.6

Sell

Buy

© Stoxcraft

Roivant Sciences Ltd.

Roivant Sciences Ltd. stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Roivant Sciences Ltd. do? Business model and key facts

Get the full picture of Roivant Sciences Ltd.: what it builds, where it operates, and how it makes money.

Roivant Sciences Ltd. Profile

Sector: Healthcare

Industry: Biotechnology

Employees (FY): 721

Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.

Company facts

Matthew Gline

CEO

721

Employees worldwide

Performance

200.61%

Last 12 months

248.06%

Last 5 years

Growth

$8.26M

Revenue year

$-397,907,000

Net income

Valuation

$24.82B

Market Cap

-64.42

Price/Earnings Ratio

Stocks related to Roivant Sciences Ltd.

Selected based on industry alignment and relative market positioning.

ONC

BeOne Medicines AG

312.68

+0.21%

3.8

Sell

Buy

© Stoxcraft

BeOne Medicines AG

ALNY

Alnylam Pharmaceuticals, Inc.

270.42

+1.10%

6.2

Sell

Buy

© Stoxcraft

Alnylam Pharmaceuticals, Inc.

RVMD

Revolution Medicines, Inc.

185.50

-0.35%

5.7

Sell

Buy

© Stoxcraft

Revolution Medicines, Inc.

MRNA

Moderna, Inc.

61.30

-0.84%

7.5

Sell

Buy

© Stoxcraft

Moderna, Inc.

INSM

Insmed Incorporated

107.60

-0.66%

8.8

Sell

Buy

© Stoxcraft

Insmed Incorporated

Events and news impacting Roivant Sciences Ltd. stock

Earnings, coporate decisions and industry developments that can affect the share price.

Toroshi scanning UNH healthcare mech before earnings — Stoxcraft score analysis

UnitedHealth (UNH) nears its 52-week high ahead of its earnings date. The score isn't buying it.

5 min 19 sec read

UnitedHealth (UNH) nears its 52-week high ahead of its earnings date. The score isn't buying it.

UnitedHealth (UNH) sits 2% below its 52-week high. The stock is up 41% in a year. Its own scorecard is not nearly as impressed.

HypeMeter-img

Slightly Bullish

Toroshi presents five stock fighters labeled ACMR, MXL, HUM, BJRI, and SN in a futuristic low-poly arena.

June's 5 strongest-trending stocks: the fundamentals aren't equal

5 min 24 sec read

June's 5 strongest-trending stocks: the fundamentals aren't equal

Humana just hit a 52-week high. Analysts keep raising price targets. Its performance score still says something's off.

HypeMeter-img

Slightly Bullish

Top Healthcare Stocks in 2026: UTHR, KRYS, and LLY

The three healthcare stocks with the strongest fundamentals in 2026

5 min 52 sec read

The three healthcare stocks with the strongest fundamentals in 2026

One healthcare stock just hit a score no other company has ever reached. The fundamentals are that clean. Here are the three names leading the sector right now.

HypeMeter-img

Slightly Bullish

Stoxcraft 2026 health score screen shows only 8% of stocks reaching top-tier fundamentals

Health score distribution 2026: what 3,884 stocks reveal about fundamental quality

2 min 31 sec read

Health score distribution 2026: what 3,884 stocks reveal about fundamental quality

We scored 3,884 stocks on fundamental health. Most are average. Only 8% clear the top threshold. If you've ever wondered which sectors dominate on fundamentals in 2026, the distribution answers it.

HypeMeter-img

Low Risk Stocks 2026: Only 5 Survived the Stoxcraft Screener

Low risk stocks 2026: Stoxcraft health score screener

5 min 58 sec read

Low risk stocks 2026: Stoxcraft health score screener

Most "low risk" stocks are just slow. We screened 3,487 stocks for the combination of low volatility AND strong fundamentals. Only 5 made the cut. These are the names the screener found.

HypeMeter-img

Why is Eli Lilly down 23% while Mounjaro keeps growing?

Why is Eli Lilly down 23% while Mounjaro keeps growing?

Company Spotlight

4 min 12 sec read

Why is Eli Lilly down 23% while Mounjaro keeps growing?

Lilly grew revenue 43% last quarter. Its stock is down 23% since January. Today's Q1 2026 earnings decide which story the market believes.

HypeMeter-img

A futuristic low-poly bull in a high-tech lab outfit scans a glowing DNA strand, highlighting how deeper analysis can reveal hidden signals and overlooked value in biotech data like United Therapeutics.

United Therapeutics stock: what the data says about UTHR

8 min 46 sec read

United Therapeutics stock: what the data says about UTHR

United Therapeutics carries a Health Score of 99 out of 100 and a net margin above 41%. Up 66% in 12 months. Here's what the fundamentals show.

HypeMeter-img

Slightly Bullish

A focused bull analyzes a glowing DNA structure inside a futuristic lab, symbolizing the complexity behind biotech innovation. While most investors see uncertainty, the real value often lies in understanding what others overlook.

United Therapeutics (UTHR) is the most undervalued large-cap biotech right now

Tech & Innovation

6 min 20 sec read

United Therapeutics (UTHR) is the most undervalued large-cap biotech right now

United Therapeutics just posted a fourth straight year of record revenue. It's debt-free, generating $4.7B in cash, and trades at half the P/E of its peers. The market still hasn't figured this one out.

HypeMeter-img

Low-poly, gaming-inspired hospital scene featuring the Stoxcraft bull as a doctor holding a large GLP-1 injector while consulting a patient, symbolizing Hims &amp; Hers expanding into weight-loss treatments.

HIMS stock up 57%: what the Novo deal really means

8 min 46 sec read

HIMS stock up 57%: what the Novo deal really means

Hims & Hers just had its best week on record. Novo Nordisk dropped the lawsuit. Now HIMS sells Ozempic and Wegovy at $149–$299/month. This changes everything.

HypeMeter-img

Stylized low-poly bull real estate investor standing in a commercial property district, looking at a glowing “667 Streak” sign symbolizing Realty Income’s record of consecutive monthly dividend payments.

The dividend stock that hasn't missed a payment in 30 years

6 min 41 sec read

The dividend stock that hasn't missed a payment in 30 years

Realty Income has paid investors every month for 30 years straight. That streak survived 2008 and COVID without a single miss. The stock's Stoxcraft scores tell a more complicated story.

HypeMeter-img

Low poly bull observing falling domino blocks labeled margin, options, debt and leverage during market selloff

11 February 2026

Are markets overleveraged? Why this selloff feels different

11 February 2026

3 min 31 sec read

Are markets overleveraged? Why this selloff feels different

Red days stacking up. But is this just fear… or leveraged positioning getting flushed out?

HypeMeter-img

Low-poly bull warrior in a futuristic arena symbolizing stock market comebacks in 2026

18 January 2026

Comeback stocks with real fundamentals: NKE, NVO, UNH, and TTD

18 January 2026

5 min 41 sec read

Comeback stocks with real fundamentals: NKE, NVO, UNH, and TTD

The strongest recoveries don't start when everything is fixed. They start when the price still reflects the pain and the business already hasn't. NKE, NVO, TTD, and UNH all carry that setup right now.

HypeMeter-img

Toroshi leads five market force heroes representing rates, cash flow, AI infrastructure, geopolitics, and liquidity.

07 January 2026

The 5 biggest forces shaping the stock market outlook

07 January 2026

8 min 47 sec read

The 5 biggest forces shaping the stock market outlook

Markets don't move on headlines. They move on forces most people miss until it's too late. Here are the five that are shaping where stocks go next.

HypeMeter-img

Slightly Bullish

Best Performing Stocks Right Now Across All 11 Market Sectors

13 October 2025

Who's really winning the market right now

13 October 2025

18 min 33 sec read

Who's really winning the market right now

Thirty-three stocks. Eleven sectors. One cheat sheet. Most people only watch tech. That's a mistake. Here's who's really winning the market right now.

HypeMeter-img

Slightly Bullish

Roivant Sciences Ltd. fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.